Primer caso de fungemia asociada a catéter por Candida nivariensis en la Península Ibérica

López-Soria, Leyre; Bereciartúa, Elena; Santamaría, M. Quintanilla; Soria, L.; Hernández-Almaraz, José Luis; Mularoni, Alessandra; Nieto, Javier; Montejo, Miguel

doi:10.1016/j.riam.2012.09.001

Cited by 21 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, phenotypic tests were not able to discriminate among the three species of the C. glabrata complex; therefore, molecular methods were applied to confirm the identification of this clinical strain ( Alcoba-Flórez et al. 2005b , Wahyuningsih et al 2008 , Romeo et al 2009 , Enache-Angoulvant et al 2011 , López-Soria et al 2013 ).…”

Section: Resultsmentioning

confidence: 99%

“…According to a simple review of the current published literature (Alcoba-Flórez et al 2005a, Fujita et al 2007 , Borman et al 2008 , Wahyuningsih et al. 2008 , Lockhart et al 2009 , Chowdhary et al 2010 , Gorton et al 2013 , López-Soria et al. 2013 , Sharma et al 2013 , Li et al 2014 , Swoboda-Kopeć et al 2014 , Tay et al 2014 , Feng et al 2015 ), 55 isolates of C. nivariensis have been described in 35 cases in European countries, 19 cases in Asia, and one case report in Australia ( Table I ).…”

Section: Resultsmentioning

confidence: 99%

“…MALDI-TOF analyses were later demonstrated to be an efficient tool to differentiate these species ( Gorton et al 2013 ). Since then, other cases have been reported in Europe ( Borman et al 2008 , Gorton et al 2013 , López-Soria et al 2013 , Swoboda-Kopeć et al 2014 ), Asia ( Fujita et al 2007 , Wahyuningsih et al 2008 , Chowdhary et al 2010 , Sharma et al 2013 , Li et al 2014 , Tay et al 2014 , Feng et al 2015 ), and Australia ( Lockhart et al 2009 ). The total number of C. nivariensis isolates described in the literature has been low in these countries.…”

mentioning

confidence: 99%

See 2 more Smart Citations

First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes

Figueiredo-Carvalho

Ramos

Barbedo

et al. 2016

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

This study evaluated the antifungal susceptibility profile and the production of potential virulence attributes in a clinical strain of Candida nivariensis for the first time in Brazil, as identified by sequencing the internal transcribed spacer (ITS)1-5.8S-ITS2 region and D1/D2 domains of the 28S of the rDNA. For comparative purposes, tests were also performed with reference strains. All strains presented low planktonic minimal inhibitory concentrations (PMICs) to amphotericin B (AMB), caspofungin (CAS), and voriconazole. However, our strain showed elevated planktonic MICs to posaconazole (POS) and itraconazole, in addition to fluconazole resistance. Adherence to inert surfaces was conducted onto glass and polystyrene. The biofilm formation and antifungal susceptibility on biofilm-growing cells were evaluated by crystal violet staining and a XTT reduction assay. All fungal strains were able to bind both tested surfaces and form biofilm, with a binding preference to polystyrene (p < 0.001). AMB promoted significant reductions (≈50%) in biofilm production by our C. nivariensis strain using both methodologies. This reduction was also observed for CAS and POS, but only in the XTT assay. All strains were excellent protease producers and moderate phytase producers, but lipases were not detected. This study reinforces the pathogenic potential of C. nivariensis and its possible resistance profile to the azolic drugs generally used for candidiasis management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes

Figueiredo-Carvalho

Ramos

Barbedo

et al. 2016

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…The strains were isolated from blood, bronchoalveolar lavage fluid (BALF) and urine of three patients over a 3-year study period (Alcoba-Flórez et al 2005). Current knowledge indicates that this species occurs worldwide and the number of published cases reaches 108 in Europe (Spain, the UK, France, Poland) (Borman et al 2008; Gorton et al 2013; López-Soria et al 2013; Parmeland et al 2013; Swoboda-Kopeć et al 2014; Aznar-Marin et al 2016; Angoulvant et al 2016), 31 in Asia (Japan, Indonesia, India, China, Malaysia) (Fujita et al 2007; Wahyuningsih et al 2008; Chowdhary et al 2010; Sharma et al 2013; Li et al 2014; Tay et al 2014; Feng et al 2015; Hou et al 2017), 11 in Australia (Lockhart et al 2009; Pinto et al 2011), four in Latin America (Argentina and Brazil) (Morales-López et al 2016; Figueiredo-Carvalho et al 2016) and one case in Africa (Burkina Faso) (Sanata et al 2014).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of human pathogens of the clade Nakaseomyces in a culture collection—the first report on Candida bracarensis in Poland

et al. 2018

View full text Add to dashboard Cite

Human pathogens belonging to the Nakaseomyces clade include Candida glabrata sensu stricto, Candida nivariensis and Candida bracarensis . Their highly similar phenotypic characteristics often lead to misidentification by conventional laboratory methods. Therefore, limited information on the true epidemiology of the Candida glabrata species complex is available. Due to life-threatening infections caused by these species, it is crucial to supplement this knowledge. The aim of the study was to estimate the prevalence of C. bracarensis and C. nivariensis in a culture collection of C. glabrata complex isolates. The study covered 353 isolates identified by biochemical methods as C. glabrata , collected from paediatric and adult patients hospitalised at four medical centres in Southern Poland. The multiplex PCR was used to identify the strains. Further species confirmation was performed via sequencing and matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) analysis. One isolate was recognised as C. bracarensis (0.28%). To our knowledge, it is the first isolate in Poland. C. glabrata sensu stricto species has been confirmed for all the remaining isolates. No C. nivariensis was found. Our study has shown that the prevalence of C. nivariensis and C. bracarensis strains is infrequent. However, it should be emphasised that the incidence of these strains may differ locally and depend on environmental factors and the population.

show abstract

“…Moreover, two of our patients died despite treatment with FLC plus AMB deoxycholate and AMB plus CSP. Considering that there is limited information with regards to treatment options and outcomes of patients infected with C. nivariensis, it appears that the sole reliance on FLZ and CSP does not seem enough to resolve candidemia and vaginitis caused by this species [24,26,27], while a combination of VRC plus MCF followed by micafungin alone [23] or CSP plus catheter removal [27] for candidemia cases and oral VCZ [24] for recurrent vaginitis cases showed successful treatment outcomes. A higher efficacy of MCF for clearance of infections caused by C. glabrata might be behind the fact that this drug causes mutations in HS1 of FKS1 and FKS2 approximately 11 times less than CSP and five times AND [28].…”

Section: Variability In Antifungal Susceptibility Patterns and Clinicmentioning

confidence: 99%

Molecular characterization and antifungal susceptibility testing of Candida nivariensis from blood samples – an Iranian multicentre study and a review of the literature

Arastehfar

Daneshnia

Salehi

et al. 2019

Journal of Medical Microbiology

View full text Add to dashboard Cite

Four isolates of C. nivariensis were deposited in the culture collection of Westerdijk Fungal Biodiversity Institute (accession numbers CBS 15642-15645). Sequences of the large subunit and internal transcribed sequences of rDNA and hotspot 1 of FKS1 and FKS2 were deposited in GenBank under the accession numbers, MK503934-MK503937, MK503955-MK503958, and MK509355-MK509362. †These authors contributed equally to this work Two supplementary tables are available with the online version of this article.

show abstract

Primer caso de fungemia asociada a catéter por Candida nivariensis en la Península Ibérica

Cited by 21 publications

References 10 publications

First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes

First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes

Prevalence of human pathogens of the clade Nakaseomyces in a culture collection—the first report on Candida bracarensis in Poland

Molecular characterization and antifungal susceptibility testing of Candida nivariensis from blood samples – an Iranian multicentre study and a review of the literature

Contact Info

Product

Resources

About